Becton, Dickinson and Company (NYSE: BDX) and AngioDynamics (NASDAQ:ANGO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitabiliy, institutional ownership, risk and dividends.
Institutional & Insider Ownership
75.4% of Becton, Dickinson and Company shares are owned by institutional investors. Comparatively, 84.2% of AngioDynamics shares are owned by institutional investors. 1.4% of Becton, Dickinson and Company shares are owned by company insiders. Comparatively, 1.9% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Becton, Dickinson and Company has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.
Earnings and Valuation
This table compares Becton, Dickinson and Company and AngioDynamics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Becton, Dickinson and Company||$12.32 billion||3.42||$3.20 billion||$6.05||32.69|
|AngioDynamics||$356.15 million||1.66||$49.13 million||($0.72)||-22.33|
Becton, Dickinson and Company has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations and price targets for Becton, Dickinson and Company and AngioDynamics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Becton, Dickinson and Company||1||3||6||1||2.64|
Becton, Dickinson and Company presently has a consensus target price of $184.10, suggesting a potential downside of 6.92%. AngioDynamics has a consensus target price of $18.50, suggesting a potential upside of 15.05%. Given AngioDynamics’ higher possible upside, analysts plainly believe AngioDynamics is more favorable than Becton, Dickinson and Company.
Becton, Dickinson and Company pays an annual dividend of $2.92 per share and has a dividend yield of 1.5%. AngioDynamics does not pay a dividend. Becton, Dickinson and Company pays out 48.3% of its earnings in the form of a dividend. Becton, Dickinson and Company has increased its dividend for 45 consecutive years.
This table compares Becton, Dickinson and Company and AngioDynamics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Becton, Dickinson and Company||10.67%||25.37%||7.92%|
Becton, Dickinson and Company beats AngioDynamics on 12 of the 17 factors compared between the two stocks.
About Becton, Dickinson and Company
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company’s BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.
AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company’s BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285409/angiodynamics-ango-versus-becton-dickinson-and-company-nysebdx-head-to-head-analysis.html
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.